Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd.

Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. is a comprehensive pharmaceutical research and development enterprise listed on the ChiNext board of the Shenzhen Stock Exchange in 2021. The company focuses on technology development and integrates innovation with a full value chain approach, providing a range of services to pharmaceutical companies and R&D investment enterprises. The company's main business lines include entrusted pharmaceutical technology R&D services (CRO), R&D technology achievement transformation services, and customized R&D and production services (CDMO). Hangzhou Bio-Sincerity Pharma-Tech is dedicated to advancing drug development, particularly for respiratory system diseases, mental and neurological disorders, tumors, and immune-related diseases. Its operations encompass the entire drug R&D and industrialization process, including target design, validation, compound preparation, clinical trials, and global registration, supported by strong R&D capabilities and a robust quality management system.

The company focuses on the forefront of innovation. Through the construction of AI models with independent intellectual property rights, the applied research of biochips, and the establishment of organoid libraries, it explores and innovates new R & D models. Based on the above - mentioned technologies, the company conducts innovative R & D of drugs for respiratory system diseases, mental and neurological diseases, tumors, and immune - related diseases. Its business covers the entire chain of drug R & D and industrialization services, including target design, target validation, compound preparation, drug - likeness evaluation, efficacy evaluation, pharmaceutical research, clinical trials, data management and statistics, patent design, global registration and application, CDMO/CMO, etc.